

Neurodegenerative Drugs: Market Research Report

<https://marketpublishers.com/r/N56BC8F5362EN.html>

Date: April 2010

Pages: 1108

Price: US\$ 3,950.00 (Single User License)

ID: N56BC8F5362EN

Abstracts

This report analyzes the worldwide markets for Neurodegenerative Drugs in US\$ Million by the following disease types: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Neurodegenerative Diseases.

The report provides separate comprehensive analytics for the US, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 165 companies including many key and niche players such as Amarin Corporation PLC, AstraZeneca PLC, Avanir Pharmaceuticals, Inc., Avigen, Inc., Bayer Schering Pharma AG, Boehringer Ingelheim GmbH, Biogen Idec Inc., Bristol-Myers Squibb Co., Biovail Corporation, Ceregene, Inc., Eisai, Inc., Elan Pharmaceuticals, Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline PLC, H. Lundbeck A/S, Merz Pharmaceuticals GMBH, Merck Serono SA, Mitsubishi Tanabe Pharma Corporation, Neurologix, Inc., NeuroSearch A/S, Novartis AG, Pfizer, Inc., Sanofi-aventis S.A, Shire Pharmaceuticals Group PLC, Teva Pharmaceutical Industries Limited, Valeant Pharmaceuticals International, and Wyeth Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Others

Huntington's Disease

Neuropathic Pain

Prion Disease

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW

Global Market Analysis

Global Market Analysis by Disease Type

Neurodegenerative Drugs – The Next Big Thing in Healthcare

Alzheimer's and Parkinson's Market

Factors Affecting the Market

Major Growth Drivers Ahead

Major Growth Inhibitors

Rapid Growth of Aging Population

Table 1. Global 65+ Age Group Population in Millions (includes corresponding Graph/Chart)

Higher Alzheimer's and Parkinson's Prevalence

Price Hikes and Government Caps

Future Holds Promise!

Research & Development

Neuroscience Research Focused on Neurodegenerative Diseases
Neuroscience Research Advances to Make a Mark...
Summary of Major Neuroscience Research Developments in 2009

2.A REVIEW OF SELECT NEURODEGENERATIVE DRUGS MARKETS

A. Alzheimer's Market in Review

The AD Epidemiology

Table 2. World Alzheimer's Disease Prevalence by Country/Region: Number of Patients in US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), Asia-Pacific (Australia, India, Philippines and Rest of Asia-Pacific), Brazil and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Table 3. Alzheimer's Disease Statistics in Top Seven Countries (US, Japan, Germany, France, UK, Italy and Spain): Number of Patients Diagnosed and Treated by Disease Severity (Mild Stage, Moderate Stage, and Late Stage) in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

The Impact of Dementia

A Look At AD Demographics

A Global Overview

Geographic Overview

Growth Drivers

Aging Baby Boomers - The Market's Growth Engine

Table 4. AD Frequency Rates in the US and Europe: Percentage Share by Age Group (includes corresponding Graph/Chart)

Unmet Medical Needs Drive Market Growth

Growth Restrains

Misdiagnosis

Lack of Awareness

High Cost of Treatment

Market Outlook for Anti-AD Drugs

Cholinesterase Inhibitors – The Leader, but Not Strong Growth Contender

NMDA Receptor Antagonists – Dynamic Growth Potential, Albeit A Small Base
Approval of Anti-AD Drugs (Cholinesterase Inhibitors) in Select Countries
Competitive Landscape
B. The Parkinson's Market in Review
The PD Epidemiology

Table 5. World Parkinson's Disease Prevalence by Country/Region: Number of Patients in the US, Canada, Japan, Europe (Germany, France, UK, Italy, Spain and Rest of Europe), China and Rest of World in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

A Global Overview
Dominance of Dopamine Agonists
Stalevo Continues to Outshine
The Slippery Path to Clinical Success
Market Drivers
Emergence of Dopamine Agonists as First Line Treatment
The Debut of Stalevo
High Unmet Clinical Needs
Market Inhibitors
Lack of Awareness and Under-diagnosis
Limitations of Existing Medicines
Restricted Period Use of Dopamine Agonists
Generic Competition from L-Dopa and Carbidopa
C. The Multiple Sclerosis Market in Review
The MS Epidemiology

Table 6. World Multiple Sclerosis Prevalence in Thousands by Select Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Facts About Multiple Sclerosis
Market Overview
Interferon-based Drugs Lead Multiple Sclerosis Drugs Market
High Unmet Need and Rich Pipeline to Expand MS Market
Sales Dip Inevitable for Current Therapies
Tough Times Ahead for Betaseron
Competitive Landscape

Table 7. Global Multiple Sclerosis Market by Leading Drugs (2008 & 2009): Percentage Share Breakdown for Copaxone, Avonex, Rebif, Betaseron, and Tysabri (includes corresponding Graph/Chart)

D. The ALS Market in Review

The ALS Epidemiology

Market Overview

Sanofi-aventis – The ALS Drugs Market Leader

E. The Huntington's Market in Review

The HD Epidemiology

Market Outlook

F. Neuropathic Pain Market in Review

Market Overview

G. Prion Disease

Disease Origin

3.FUTURE THERAPIES

Alzheimer's Disease

Select Pipeline Drugs for Alzheimer's Disease

Parkinson's Disease

Select Pipeline Drugs for Parkinson's Disease

Huntington's Disease

Select Pipeline Drugs for Treatment of Huntington's Disease

Multiple Sclerosis

Oral Pipeline Drugs to Alter Market Dynamics in MS Therapies

Select Pipeline Drugs for Multiple Sclerosis

Amyotrophic Lateral Sclerosis

Select Pipeline Drugs for Amyotrophic Lateral Sclerosis

4.NEURODEGENERATIVE DISEASES OVERVIEW

Neurodegeneration

An Overview of Factors that Link Neurodegenerative Diseases

Genetics

Intracellular Mechanisms

Protein Degradation Pathways

Mitochondrial Dysfunction
Axonal Transport
Programmed Cell Death
An Overview of Select Major Neurodegenerative Diseases
Alzheimer's Disease
Definition
Cause
Diagnoses
Prevention
Treatment
Anti-AD Drug Classes and Approved Products
Parkinson's Disease
Definition
Cause
Diagnosis
Therapeutic Treatment
List of Drugs Available for the Treatment of Parkinson's Disease
Surgical Intervention
Multiple Sclerosis
Definition
Types of Multiple Sclerosis

Table 8. Prevalence of Different Types of Multiple Sclerosis (includes corresponding Graph/Chart)

Etiology
Pathology
Treatment
List of Approved Multiple Sclerosis Drugs
Huntington's Disease
Definition
Prognosis
The Three Stages of HD
Symptoms and Signs
List of Physical, Psychiatric and Cognitive Symptoms in Huntington's Disease
Diagnosis
Treatment
Amyotrophic Lateral Sclerosis (ALS)

Definition
Types of ALS
Familial ALS
Sporadic ALS
Guamanian ALS
Etiology
Symptoms
Diagnosis
Treatment

5. AN OVERVIEW OF NEURODEGENERATIVE DRUGS FOR SELECT DISEASES

Neurodegenerative Drugs for Alzheimer's Disease

NMDA Receptor Antagonists (NMDARA)

Memantine

Cholinesterase Inhibitors (ChEIs)

Donepezil (Aricept)

Rivastigmine (Exelon)

Galantamine Hydrobromide (Razadyne)

Tacrine (Cognex)

Other Alternatives

Vitamin E

Estrogen Therapy

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

Gingko Biloba

Neurodegenerative Drugs for Parkinson's Disease

Dopaminergic Agents

Levodopa/Carbidopa

Dopamine Agonists

Bromocriptine/Parlodel

Ropinirole/Requip

Pramipexole/Mirapex

Cabergoline/Dostinex

Apomorphine/Apokyn

Other PD Drugs

COMT Inhibitors

MAO-B Inhibitors

Dopamine Amplifiers

Anticholinergics

Neurodegenerative Drugs for Huntington's Disease

Tetrabenazine

Others

Neurodegenerative Drugs for Multiple Sclerosis

Interferon Drugs

Beta Interferon Drugs for the Treatment of Multiple Sclerosis

Non-Interferon Drugs

Non-Interferon Drugs for the Treatment of Multiple Sclerosis

Neurodegenerative Drugs for Amyotrophic Lateral Sclerosis

Rilutek

Symptomatic Treatment

6.NEURODEGENERATIVE RESEARCH

Neurologix's Non-dopamine Gene Therapy for PD

Cell Cure's Cell Replacement Therapy for PD

Researches Developing Neuroprotective Agent for PD

UT Southwestern Researchers Study New Compound for HD

UCLA Scientists Identify Molecular Switch Capable of Blocking HD

Repligen Reports Detection of HDAC 3 Drug Target for Friedreich's Ataxia (US)

Tel Aviv University Reports Stem Cell Cure for Neurodegeneration (Israel)

Cambridge Researchers Develop Novel Drug Targets for HD

Emory Research Team Develops First Transgenic Monkey Model of HD

KeyNeurotek Pharma Discloses Molecular Pathomechanism of HD Mutation

Researchers Identify New Gene for ALS

Q Therapeutics and Johns Hopkins Research Team to Study GRPs in ALS Model

ALS TDI and CSC Collaborate to Study Stem Cells Use in ALS Treatment

Allen Institute and ALS TDI to Conduct ALS Study

Life Technologies to Develop Neurodegenerative Disease Models

Neuralstem and University of Michigan Collaborate for ALS Research

ALS TDI and MDA Collaborate for ALS Drug Discovery

7.SELECT CLINICAL TRIALS

Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA

Medivation's Dimebon Fails to Meet End Points in Phase III Trial

QR Pharma Annuls Phenserine Production

Neurologix Begins Phase II Studies for Parkinson's Disease Treatment (US)

Biovail and ACADIA Complete Phase II Clinical Trials for Pimavanserin (Canada, US)

Merck Serono Announces Encouraging Phase III Results of Oral Mylinax
Alnylam and Medtronic Present New Preclinical Data on ALN-HTT
NeuroSearch Presents ACR16 as Novel Huntington's Disease Therapy
Eli Lilly Launches Two Phase-III Trials for Solanezumab(i) Worldwide (US)
Teva and Active Biotech Obtains Fast Track Status from FDA for Oral Laquinimod
CytRx Initiates Phase II/III Clinical Trial for Arimoclomol
Synosia Therapeutics Starts Stage-I Clinical Trial for SYN-120 (Switzerland)
H. Lundbeck Begins Phase-I Clinical Tests for Lu 02-750 (Denmark)
Anavex Life Sciences Selects FORENAP Pharma EURL for ANAVEX 2-73 Phase-I
Clinical Tests (Switzerland)
Bayer Schering Pharma Completes Stage-II Trials for BAY 94-9172 (Germany)
Newron and Merck Serono Start Second Round of Phase III Tests for Safinamide (Italy)
Biogen Idec Secures Fast Track Designation from US-FDA for PEGylated Interferon
Beta-1a
ExonHit Therapeutics Completes Phase-II Clinical Study for EHT 0202 (France)
Kyowa Hakko Kirin to Start Phase-III Clinical Trials for Istradefylline in Japan
Medtronic and Alnylam Pharma Report Pre-Clinical Results of ALN-HTT (US)
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's Treatment
NeuroSearch Begins Critical Phase III Program with ACR16
Avicena to Proceeds with Phase III Trial of HD-02
Knopp Neurosciences Commences Phase II Study of KNS- 760704
Maas Biolab SBIR Initiates Phase II for Cyclosporin
MediciNova Announces Phase II Clinical Trial Results of MN-166
Avicena Proceeds to NIH Sponsored Phase III Trial for HD-02
EnVivo Pharmaceuticals Progresses on Major HDACi Program
NeuroSearch Files CTA in Europe to Begin Clinical Phase III Program with ACR16

8.PRODUCT INTRODUCTIONS/ APPROVALS/ DEVELOPMENTS

Acorda Therapeutics Obtains FDA Approval for Fampridine-SR to treat Multiple
Sclerosis
Novartis Obtains Priority Review Status for Oral Fingolimod from US FDA
Accera Introduces Axona™
Eisai Receives Approval for Aricept®
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of
MS
Copaxone Receives FDA Approval for Patients with First Clinical Episode Suggestive of
MS
Novartis Obtains FDA Approval for Extavia

ArmaGen Develops IgG-Decoy Receptor Fusion Protein (US)
Knopp's KNS-760704 Receives EC Orphan Designation
NeuroSearch Receives EMEA Approval for Huntexil™ Brand Name (Europe)
Cambridge Labs Receives Spanish Marketing Approval for Tetrabenazine
ArmaGen Technologies Secures Orphan Drug Designation for AGT-181 from FDA (US)
Raptor Pharmaceuticals Receives FDA Orphan Drug Designation for Cysteamine
Elan and Biogen Receive Health Canada Approval for MS Use of Tysabri™
Exelon Patch Wins EU Approval for Alzheimer's Treatment
Isis Pharma Receives Orphan Drug Designation for ISIS333611

9.RECENT INDUSTRY ACTIVITY

Lundbeck Acquires LifeHealth
StemCells Acquires Stem Cell Sciences
Oryzon Takes Over Crystax Pharmaceuticals
JANSSEN Acquires Elan's Alzheimer's Immunotherapy Program
Hisamitsu Takes Over Noven Pharmaceuticals
Lundbeck Takes Over Ovation Pharmaceuticals
Valeant Pharmaceuticals Takes Over Dow Pharmaceutical Sciences
Genzyme Acquires Assets of Targeted Genetics Corporation
Merck Takes Over Insmed's Follow-on Biologics Assets
NeuroSearch Reacquires Global Rights to ACR16
Biovail Acquires Worldwide Rights to Tetrabenazine
Raptor Pharmaceuticals Merges with TorreyPines
iZumi Bio Merges with Pierian; Forms iPierian, Inc.
Cell Genesys Merges with BioSante Pharmaceuticals
CeNeRx BioPharma Secures Marketing and Development Rights for CXB909
Laureate Pharma and ZZ Biotech Ink Agreement
QxPharma Limited Signs Agreement with Patheon
Cambridge Labs Signs New Agreements to Market Xenazine® in North America
Shire and UCB Ink Agreement
NeuroNova and Genentech Signs Agreement for VEGF Use in ALS Treatment
Biovail to Acquire North American Rights to Fipamezole from Santhera
Phytopharm Inks Agreement with CHDI Foundation to Evaluate Cogane
KineMed Collaborates with Bristol-Myers Squibb
Vitae Pharmaceuticals Collaborates with Boehringer Ingelheim
Insmed Inks Deal with IDIS to Organize NPPs for IPLEX™
Genzyme Corp. and Bayer HealthCare Sign Agreement
CHDI Foundation Inks Agreement with AMRI for Drug Discovery

Addex Pharmaceuticals Inks Licensing Agreement with Merck
Acccera Sets Up Neura Pharmaceuticals
Evotec Inks Research Agreement with Biogen Idec
ALS TDI and Asklepios to Develop ALS Therapy Delivery Alternatives
Evotec Extends Collaboration with Boehringer Ingelheim
Neuralstem Collaborates to Develop Neural Stem Cell Therapies
Eisai and Pfizer Ink Agreement
BioAdvance Invests in TREVENTIS Corp.
AstraZeneca Announces Milestone Payments to Targacept for AZD3480 Program
Suven Life Sciences Secures Two Patents in the US
Eisai Terminates Contract with Nitto Denko Corporation
MJFF Awards Grants to Targacept
Metabolic Solutions Receives Grant from Alzheimer's Drug Discovery Foundation
Medical Research Council and Wellcome Trust to Fund Neurodegeneration Research
Biovail Acquires Prestwick Pharmaceuticals
GlaxoSmithKline Acquires Sirtris Pharmaceuticals
Newron Pharmaceuticals Acquires Hunter-Fleming
SYGNIS Pharma Purchases Amnestix
Proximagen Neuroscience Acquires Cambridge Biotechnology
Teva Acquires Barr Pharmaceuticals
Eisai Acquires MGI Pharma
Ovation Pharmaceuticals Acquires License to Commercialize Xenazine® in the US
Targeted Genetics Acquires Rights to the siRNA Development Program
Insmed Obtains Royalty-Free Global Rights for IPLEX™
Pfizer and Serenex Ink Agreement
Dr. Reddy's Laboratories Inks Agreement with Sygnis Pharma
Cambridge Labs Inks and Renews Agreements in Multiple Nations
CHDI Inked Collaboration Agreements with Galapagos
Power3 Medical Products and StemTroniX Sign Letter of Intent
ALS Therapy Development Institute and Allen Institute Ink Agreement
Yissum Inks Licensing Agreement with Eucalyptus
GlaxoSmithKline Biologicals Enters into Licensing Agreement with AFFiRiS
Neurologix and Aegera Therapeutics Ink Licensing Agreement
Neurobiological Inks Licensing Agreement with BIAR
Raptor Pharma Forms Collaboration with CHU d'Angers for Phase II Trial
Amorfix Completes Research Partnership with Biogen Idec
Apitope Raises Financing for Developing Multiple Sclerosis Compound
Pipex Pharmaceuticals Changes Corporate Name to Adeona Pharmaceuticals
MethylGene Terminates Collaboration Agreement with EnVivo Pharmaceuticals

Varinel Receives Fund from Alzheimer's Drug Discovery Foundation
Pharmatrophix Receives Grants from Alzheimer's Drug Discovery Foundation
Eisai Acquires Morphotek
Transition Therapeutics Acquires NeuroMedix
Merz Licenses Anti-Alzheimer's Drug Technology from TAU
Intellect Neurosciences Inks Agreement with CHDI Foundation to Evaluate Potential of OXIGONTM
Intellect Signs Licensing Agreement with Immuno- Biological Laboratories
Boehringer Ingelheim Signs R&D Agreement with Ablynx
Evotec Teams Up with Boehringer Ingelheim
Siemens Medical Signs Partnership Agreement with Wyeth
Pipex Pharma Signs Agreement for Evaluation of COPREXA
Digilab Receives Notice of Allowance for New Alzheimer's Biomarker
Pfizer Joins Forces with Genizon for AD
Avicena Teams Up with NINDS for Phase III Trial of PD-02
QSV and Artielle Sign Contract to Produce RTL-1000 (To be added to Canada)
ALS TDI Selects Microbix to Manufacture Adenoviruses
Maas BiolAB Receives SBIR Grant for ALS Study

10.FOCUS ON SELECT GLOBAL PLAYERS

Amarin Corporation PLC (Ireland)
AstraZeneca PLC (UK)
Avanir Pharmaceuticals, Inc. (US)
Avigen, Inc. (US)
Bayer Schering Pharma AG (Germany)
Boehringer Ingelheim GmbH (Germany)
Biogen Idec Inc. (US)
Bristol-Myers Squibb Co. (USA)
Biovail Corporation (Canada)
Ceregene, Inc. (US)
Eisai, Inc. (USA)
Elan Pharmaceuticals (US)
Eli Lilly and Company (USA)
Forest Laboratories, Inc. (US)
GlaxoSmithKline PLC (UK)
H. Lundbeck A/S (Denmark)
Merz Pharmaceuticals GMBH (Germany)
Merck Serono SA (Switzerland)

Mitsubishi Tanabe Pharma Corporation (Japan)
Neurologix, Inc. (US)
NeuroSearch A/S (Denmark)
Novartis AG (Switzerland)
Pfizer, Inc. (US)
Sanofi-aventis S.A (France)
Shire Pharmaceuticals Group PLC (UK)
Teva Pharmaceutical Industries Limited (Israel)
Valeant Pharmaceuticals International (US)
Wyeth Pharmaceuticals, Inc. (US)

11. GLOBAL MARKET PERSPECTIVE

Analytics by Geographic Region

Table 9. World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 10. World 10-Year Perspective for Neurodegenerative Drugs by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

Analytics by Disease Type

Table 11. World Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Disease Type – Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 12. World 10-Year Perspective for Neurodegenerative Drugs by Disease Type – Percentage Breakdown of Dollar Sales for Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and Others for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. MARKET ANALYSIS

Current & Future Analysis

AD Market Overview

Approval of Cholinesterase Inhibitors for MCI to Drive Market

Status of AD Drugs

Prevalence

Table 13. US Prevalence of Alzheimer's Disease for 2005-2010 (includes corresponding Graph/Chart)

PD Market Overview

Levodopa/Carbidopa on Declining Spree

Patent Expiry Status

Patent Expiry Status of Parkinson's Disease Drugs in the US

Prevalence

Increased Incidence and Rise in Drug Prices to Drive Growth in MS Market

Clinical Trials

Product Launches

Strategic Corporate Developments

Key Players

B. MARKET ANALYTICS

Table 14. US Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market – Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2. EUROPE

A. MARKET ANALYSIS

Current & Future Analysis

Alzheimer's and Parkinson's Prevalence in Europe

Table 15. European Alzheimer's Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart)

Table 16. European Parkinson's Disease Prevalence by Country/Region: Number of Patients for Germany, France, UK, Italy, Spain, and Rest of Europe in Thousands for Years 2001 through 2010 (includes corresponding Graph/Chart)

Table 17. Multiple Sclerosis Prevalence in Select European Countries for Years 2001 through 2010 (includes corresponding Graph/Chart)

Low Penetration to Fuel Growth in European MS DMDs Market
Clinical Trials
Product Launches/Approvals
Strategic Corporate Developments
Key Players

B. MARKET ANALYTICS

Table 18. European Recent Past, Current and Future Analysis for Neurodegenerative Drugs by Country/ Region – France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 19. European 10-Year Perspective for Neurodegenerative Drugs by Country/Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. MARKET ANALYSIS

Current & Future Analysis
Canada – High Prevalence Rates for Multiple Sclerosis

Table 20. Multiple Sclerosis Prevalence in Canada For Years 2001 through 2010 (includes corresponding Graph/Chart)

Incidence of Multiple Sclerosis on the Rise in India

Table 21. Multiple Sclerosis Prevalence in India For Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer's and Parkinson's Prevalence in Canada

Table 22. Alzheimer's and Parkinson's Diseases and Multiple Sclerosis Prevalence in Canada For Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer's and Parkinson's Prevalence in Japan

Table 23. Alzheimer's and Parkinson's Diseases Prevalence in Japan for Years 2001 through 2010 (includes corresponding Graph/Chart)

Alzheimer's Prevalence in Asia-Pacific

Table 24. Alzheimer's Disease Prevalence in Asia-Pacific by Country: Number of Patients for Australia, India, Philippines and Rest of Asia-Pacific in Thousands For Years 2001 through 2010 (includes corresponding Graph/Chart)

Clinical Trials

Research Studies/Other Developments

Product Launches/Approvals

Strategic Corporate Developments

Select Players

B. MARKET ANALYTICS

Table 25. Rest of World Recent Past, Current and Future Analysis for Neurodegenerative Drugs Market – Annual Sales in US\$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 165 (including Divisions/Subsidiaries - 190)

Region/Country/Players

The United States 93

Canada

Japan

Europe

France

Germany

The United Kingdom

Italy

Spain

Rest of Europe

Asia-Pacific (Excluding Japan)

Middle-East

I would like to order

Product name: Neurodegenerative Drugs: Market Research Report

Product link: <https://marketpublishers.com/r/N56BC8F5362EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N56BC8F5362EN.html>